Acrivon Therapeutics Execs Flood Stock with 1.4 M Shares, CFO, CEO, COO, and COO Buy 1.4 M Shares in March 2026, signaling confidence ahead of breakthrough

Insider Buying Signals a Long‑Term Bet

On March 1 2026, Chief Accounting Officer Katharine Peterson executed a sizeable purchase of 31,900 Acrivon Therapeutics shares through a stock‑option exercise. Although the transaction cost was zero and the option vesting is structured over the next four years, the sheer volume—nearly 32 k shares—signals confidence that the company’s precision proteomics platform will drive future revenue. The option terms, with 25 % vesting on March 1 2027 and the rest spread over 36 monthly installments, align with the typical biotech incentive structure that rewards executives for sustained performance, rather than a short‑term market bump.

Investor Takeaway: Confidence Amid Consolidation

Acrivon’s share price has hovered around $1.50 since the IPO, with a 52‑week range of $1.05–$5.75. The recent buy by Peterson, coupled with a cluster of option grants to other senior leaders (CEO, CFO, CMO, COO), suggests that the executive team is betting on a breakthrough in the upcoming pipeline. For investors, the move can be read as an internal signal that the company is on track to deliver clinical milestones, even if the market has yet to price this optimism. The stock’s modest volatility and lack of recent earnings announcements mean that price moves will likely lag behind insider sentiment—making the current price a potential entry point for long‑term investors.

Peterson’s Transaction Pattern: A Steady Investor

Peterson’s historical activity shows a pattern of selling small blocks of common stock (99–116 shares) in February and August 2025 and early 2026, followed by a substantial option purchase in March 2026. The sales occurred at prices between $1.39 and $1.63, while the option exercise was triggered when the market price reached $1.67. This shift from short‑term liquidity events to a long‑term equity stake indicates a transition from portfolio management to a vested interest in the company’s success. Her cumulative holdings post‑transaction stand at 4,006 shares, reflecting a modest but meaningful stake that will grow as the options vest.

Contextualizing the Deal Within Company Activity

The March 1 filings reveal a broader wave of option purchases by Acrivon’s top executives: the CEO bought 602,705 shares, the CFO 132,925 shares, and the COO 186,728 shares, among others. Such synchronized buying by the senior leadership cohort is a classic “signal of confidence” pattern, often seen before key regulatory approvals or clinical trial results. In contrast, the CEO’s recent sale of 14,265 shares in February suggests a routine portfolio rebalancing rather than a signal of distress. For the market, the aggregate insider buying of over 1.4 million shares in March 2026 represents a significant injection of shareholder alignment.

Bottom Line for Analysts and Traders

The current transaction by Peterson and the coordinated option grants to other executives paint a picture of executive optimism despite the stock’s flat performance. Investors who favor a “buy‑and‑hold” strategy may view Acrivon’s current price as undervalued relative to the potential upside implied by insider activity. Short‑term traders, however, should note that the market has yet to react strongly to these filings—providing an opportunity for incremental gains if the company delivers on its clinical roadmap.